COST-EFFECTIVENESS MODEL FOR DENOSUMAB INCORPORATING FRAX® AND ADHERENCE IN A UK SETTING

被引：0
|
作者：
Strom, O. [1 ,2 ]
Macarios, D. [3 ]
Badamgarav, E. [3 ]
Borgstrom, F. [1 ,2 ]
Jonsson, B. [1 ,4 ]
Tosteson, A. [5 ]
Kanis, J. [6 ]
机构：
[1] I3 Innovus, Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Stockholm Sch Econ, S-11383 Stockholm, Sweden
[5] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA
[6] WHO Collaborating Ctr, Sheffield, S Yorkshire, England
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF DENOSUMAB IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SCOTLAND
    Davies, A.
    Compston, J.
    Ferguson, S.
    McClosky, E.
    Shearer, A.
    Taylor, A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A310 - A310
  • [22] Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women
    Hiligsmann, Mickael
    Boonen, Annelies
    Dirksen, Carmen D.
    Ben Sedrine, Wafa
    Reginster, Jean-Yves
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (01) : 19 - 28
  • [23] Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review
    Y. Wan
    F. Zeng
    H. Tan
    Y. Lu
    Y. Zhang
    L. Zhao
    R. You
    [J]. Osteoporosis International, 2022, 33 : 979 - 1015
  • [24] Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review
    Wan, Y.
    Zeng, F.
    Tan, H.
    Lu, Y.
    Zhang, Y.
    Zhao, L.
    You, R.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2022, 33 (05) : 979 - 1015
  • [25] Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis
    Jonsson, B.
    Stroem, O.
    Eisman, J. A.
    Papaioannou, A.
    Siris, E. S.
    Tosteson, A.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 (07) : 2063 - 2065
  • [26] Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia
    Y. W. Choo
    N. A. Mohd Tahir
    M. S. Mohamed Said
    S. C. Li
    M. Makmor Bakry
    [J]. Osteoporosis International, 2022, 33 : 1909 - 1923
  • [27] Incorporating model uncertainty in cost-effectiveness analysis:: A Bayesian model averaging approach
    Negrin, Miguel A.
    Vazquez-Polo, Francisco-Jose
    [J]. JOURNAL OF HEALTH ECONOMICS, 2008, 27 (05) : 1250 - 1259
  • [28] Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis EDITORIAL COMMENT
    Punnen, Sanoj
    [J]. JOURNAL OF UROLOGY, 2018, 200 (06): : 1220 - 1220
  • [29] The Cost-Effectiveness of rFVIIIFc in a Swedish Setting
    Schlueter, M.
    Henry, N.
    Jovanovic, J.
    Lowin, J.
    Krishnan, S.
    Myren, K. -J.
    [J]. HAEMOPHILIA, 2016, 22 : 75 - 75
  • [30] Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting
    O. Ström
    C. Leonard
    D. Marsh
    C. Cooper
    [J]. Osteoporosis International, 2010, 21 : 1599 - 1608
12345